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Breast cancer is the most common cancer in
women (Parkin et al. 2001). Incidence is
highest in North America, Northern Europe,
and Australia, where age-adjusted rates are
75–92 per 100,000 women (standardized to
year 2000 world population), and lowest in
Asia and Africa, where incidence is less than
22 per 100,000 (Parkin et al. 2001).
Mortality has increased steadily from the
1960s until the late 1980s, when rates
declined in many countries, including the
United States (Parkin et al. 2001). Mortality
continued to climb, however, for African
Americans, whose mortality rates have
exceeded the U.S. average since the 1980s
(SEER 2002). Worldwide, breast cancer inci-
dence continues to rise in all age groups, with
an increase in U.S. age-adjusted incidence of
more than 40% from the early 1970s to the
late 1990s (Clegg et al. 2002; SEER 2002).
An estimated 203,500 new invasive breast
cancer diagnoses are expected in the United
States this year, 54,300 in situ cases, and
45,000 deaths (ACS 2002). About 40% of
new invasive cases are diagnosed in women
younger than 60 years of age (ACS 1996),
and breast cancer is the leading cause of can-
cer death among women 35–54 years of age
(National Center for Health Statistics 1997).
The threat to women in mid life coupled
with observations of substantial temporal and
geographic variation and poor prediction of
individual risk has prompted a search for
modiﬁable risk factors. Because breast cancer
risk changes over time and varies across geo-
graphic locations, factors associated with
these variations may provide clues that can
lead to prevention. Thus far, many correlates
of risk have been identiﬁed, including a con-
stellation of hormone-related reproductive
factors. These factors account for a substantial
portion of the variation in incidence, while
also providing evidence that additional fac-
tors, probably modest in magnitude, remain
to be discovered.
Taken together, epidemiologic studies of
hormonal factors in breast cancer and animal
studies of the hormonal activity and carcino-
genic potential of certain synthetic chemicals
suggest environmental pollutants as possible
sources of risk. Compounds identiﬁed in lab-
oratory studies as mammary carcinogens or
hormonally active are in common commer-
cial products and are ubiquitous pollutants to
which women in industrial societies are
widely exposed, so identifying effects on
breast cancer has the potential for substantial
public health impact, even if the relative risk
associated with exposure is low.
In this article we identify promising leads
in the study of environmental pollutants and
breast cancer and the challenges in pursuing
them. As background, we provide an over-
view of incidence trends and well-established
and suggested breast cancer risk factors that
inform environmental research. We review
animal studies of chemicals that may be
breast carcinogens, promote growth of breast
cells and hormonally sensitive tumors, or
affect mammary gland development and sus-
ceptibility. We assess current knowledge from
the few epidemiologic studies of environmen-
tal pollutants, discuss the barriers to further
progress, and identify research needs.
Background
Trends in incidence and mortality. The
association between breast cancer risk and
industrial development, historically and
worldwide, is one indicator of modifiable
risk. Increased access to mammography and
other forms of screening is generally believed
to play a role in rising incidence, particularly
during the early to mid-1980s, but does not
explain increases in risk before 1980 or
increasing risk for younger and older women
who are less likely to be screened or in devel-
oping countries with low screening rates
(Ursin et al. 1994).
Currently, incidence is rising most rapidly
in low-risk populations both internationally
(Parkin et al. 2001) and in the United States
(SEER 2002), suggesting that ongoing cul-
tural change is a primary contributor. For
example, incidence for Asian-American
women at the beginning of the 1990s was
40% lower than for U.S. non-Hispanic white
women but increased 19% by 1998 com-
pared with 7% increase for non-Hispanic
whites (SEER 2002).
In Los Angeles County, California, where
ethnic diversity allows for more detailed
analysis of trends in ethnic populations, inci-
dence among non-Hispanic whites is 20%
higher than for African Americans and
roughly double the rate for Hispanics and
Asian Americans; in contrast, the rates of
change are highest among Asian Americans.
Los Angeles County breast cancer incidence
rose by 1.1% per year in 1993–1997 among
non-Hispanic whites, 2.1% in Hispanics, and
4.6% in Asians, while declining by 0.3% for
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Research | ReviewAfrican Americans (Deapen et al. 2002). By
the late 1990s, rates for women of Japanese
and Filipino heritage were approaching rates
for non-Hispanic whites.
Surveillance data for Asian-American
women are consistent with studies of migrant
populations showing that when women
migrate from low- to high-risk countries and
vice versa, their risk and the risk in successive
generations change to approximate the levels
in the destination country (Kliewer and
Smith 1995). Further, a population-based
case–control study of Asian migrants to
California and Hawaii showed higher risk
associated with longer residence in the United
States (Ziegler et al. 1993); and for U.S.-born
Asian women, the study showed higher risk
for those with more U.S.-born grandparents,
an indicator of acculturation. The relative risk
associated with migration changed only
slightly after controlling for menstrual and
reproductive factors, providing evidence that
other factors contribute to migration effects
(Wu et al. 1996).
Although migration studies provide
insight into the contribution of sociocultural
factors and support the idea that heritable fac-
tors are not predominant determinants of
breast cancer risk, studies of heritable genes
add a complementary perspective. Mutations
in the breast cancer genes BRCA1 and BRCA2
are estimated to account for fewer than 10%
of cases (Claus et al. 1996), although addi-
tional genes that affect hormone synthesis and
metabolism and DNA repair likely add to her-
itable risk (Martin and Weber 2001). The
effect of the broader range of heritable genes is
seen in studies of identical (monozygotic) and
fraternal (dizygotic) twins. In a study of
45,000 twin pairs, 14% of monozygotic twins
and 9% of dizygotic twins were concordant
for breast cancer diagnosis (Lichtenstein et al.
2000), and Mack et al. (2002) reported
slightly higher concordance.
Reproductive and other previously studied
risk factors. The fact that reproductive charac-
teristics affect breast cancer risk has been
known since 1700, when Ramazzini reported
higher incidence among nuns (Spratt et al.
1995). Factors now known to confer higher
risk include older age and being female,
younger at menarche, older at menopause,
nulliparous, and older at a first live birth or
stillbirth; whereas higher parity, longer lacta-
tion, and bilateral ovariectomy are protective
(Davis et al. 1997; Kreiger et al. 1999;
Parazzini et al. 1997).
Reproductive risk factors are associated
with exposure to estradiol, progesterone, and
other hormones; and reproductive hormones
are also believed to underlie increased risk
associated with alcohol consumption, lack of
physical activity, higher body mass index and
weight gain after menopause, and low
premenopausal body mass index (Bernstein
et al. 2002). In addition, recent studies pro-
vide some evidence that in utero hormonal
exposures characteristic of certain pregnancies
affect breast cancer risk in the offspring.
Daughters exposed to lower hormone levels in
pregnancies with toxemia or pre-eclampsia are
at lower breast cancer risk, whereas higher
hormone levels in pregnancies with twins
result in higher risk (Bernstein et al. 2002).
This is a new area of research with some
inconsistencies within the limited number of
studies completed.
Pharmaceutical hormones similarly affect
risk. Both estrogen-only and estrogen-proges-
terone hormone replacement therapy (HRT)
for postmenopausal women increase breast
cancer risk. In a pooled analysis of 51 studies
involving about 54,000 postmenopausal
women, the relative risk of breast cancer for
women with at least 5 years of recent use was
1.35 [95% confidence interval (95% CI),
1.21–1.49] (Collaborative Group on
Hormonal Factors in Breast Cancer 1997).
Women who stopped using HRT more than
5 years before were not at higher risk.
Additional large-scale population-based epi-
demiologic studies show 10% increased risk
after 5 years of use for estrogen alone and 40%
after 15 years, and 30% increased risk for less
than 5 years of use for combination HRT
(Bernstein et al. 2002). In a clinical trial of
combination HRT versus placebo, the
Women’s Health Initiative reported a hazard
ratio of 1.26 (95% CI, 1.00–1.59) about
5 years after enrollment and higher risk for
women with prior HRT use up to a hazard
ratio of 1.81 (95% CI, 0.6–5.43) (Women’s
Health Initiative Investigators 2002). For oral
contraceptives, recent, but not long-term, use
is associated with higher risk (Bernstein 2002),
with about 26% increased risk for current
users (Collaborative Group on Hormonal
Factors in Breast Cancer 1996). Additional
information will become available as more
women with long-term oral contraceptive use
reach the ages of higher breast cancer risk.
Diethystilbestrol (DES), a potent synthetic
estrogen, has been linked to increased breast
cancer risk in women who took DES during
pregnancy (Colton et al. 1993; Titus-Ernstoff
et al. 2001).
Diet seems very likely to affect breast
cancer risk, as it does in animals, but epidemio-
logic studies have failed to identify specific
dietary constituents that increase or decrease
risk. Effects of fat and fruits and vegetables
have been extensively studied, so far providing
no consistent evidence of dietary risk factors
(Gandini et al. 2000; Holmes et al. 1999;
Hunter and Willett 1996; Michels 2002;
Smith-Warner et al. 2001; Willett 1999).
High soy intake in Asia has been proposed as a
factor in reduced breast cancer rates there,
although epidemiologic studies so far provide
limited evidence of a protective effect
(Adlercreutz 2002; Hilakivi-Clarke et al. 2001;
Trock et al. 2000). One recent study of Asian
Americans reported a protective effect for soy
that was most pronounced for high soy intake
beginning in adolescence (Wu et al. 2002),
and this study illustrates newer approaches to
diet that explore possible effects of the timing
of exposure. Other new approaches focus on
possible interactions of multiple aspects of diet,
for example, alcohol and folate (Feigelson et al.
2003; Zhang et al. 2003), or between diet and
genetic polymorphisms (Zheng W et al. 2002).
Ionizing radiation is a clearly established
environmental cause of breast cancer (NRC
1990). Studies of atomic bomb survivors and
women exposed to X-ray medical treatments
in childhood indicate that exposures early in
life impart greater risk than adult exposures.
In studies of exposed Japanese women 35
years after the atomic bomb, risk of breast
cancer was 4-fold greater in women younger
than 4 years of age and 2-fold greater in
women 10–14 years of age compared with
women 20–30 years of age at the time of the
bombing. Women younger than 40 years of
age had a greater risk than those older than
40 at the time of bombing (Land 1995;
Tokunaga et al. 1987).
Higher socioeconomic status (SES),
usually measured by education level and
income, is consistently associated with higher
breast cancer risk, although education and
income clearly are not themselves causal. This
relationship is often seen even after control-
ling for breast cancer risk factors such as par-
ity and age at childbearing, which are
themselves associated with SES. The possibil-
ity that some part of this relationship is due to
chemical exposures, for example, from use of
consumer products and pesticides, warrants
further study. In a small exploratory survey of
breast cancer risk factors in high- and low-
incidence neighborhoods, higher SES women
reported signiﬁcantly higher use of several dif-
ferent pesticides (home and lawn chemicals,
repellents, and lice control) and of dry
cleaning (Maxwell et al. 1999).
Role of previously studied risk factors in
incidence patterns. Women diagnosed with
breast cancer, as with other diseases, often ask
themselves, Why me? In recent years, com-
munities with high incidence have struggled
with that question as well. A few studies have
tried to address these questions at both the
individual and population levels, and these
studies are interesting because unexplained
variation can motivate and inform studies of
new hypotheses.
At the individual level, Gail et al. (1989)
developed a model that predicts risk from
a woman’s age, age at menarche, age at first
live birth, number of previous biopsies, and
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cancer; and this model has been used, among
other things, as a basis for identifying women
considered high risk as candidates for chemo-
prevention trials of treatments such as tamoxi-
fen and raloxifene. Using data on breast
cancer incidence and risk factors in two large
national surveys, Madigan et al. (1995) esti-
mated that 41% of breast cancer risk in the
United States is explained by later childbear-
ing, nulliparity, higher income, and family
history of breast cancer.
Regarding geographic patterns within the
United States, mortality is highest in the
Northeast and West and intermediate in the
Midwest compared with the South (National
Cancer Institute et al. 1999). Sturgeon et al.
(1995) reported in an ecologic analysis that
recognized breast cancer risk factors accounted
for nearly all regional variation in mortality
among women younger than 50 years of age;
however, among older women, adjustment
reduced excess incidence by 50% for the
Northeast and Midwest and 10% for the West
compared with the South. A similar analysis of
the Nurses’ Health Study improved on the
Sturgeon et al. method by adjusting at the
individual level rather than regional level for
established risk factors (Laden et al. 1997).
However, little variation in breast cancer risk
across regions was observed either before or
after adjustment, perhaps due to the relative
homogeneity in the risk-factor proﬁle of nurses
nationwide, so results are not informative.
The extent to which known breast cancer
risk factors account for geographic variation is
a subject of particular interest in areas such as
Cape Cod, Massachusetts, and Marin
County, California, where incidence is higher
than in a comparison population such as the
entire state. Surveillance data show about
20% higher risk on Cape Cod in 1982–1994
(Silent Spring Institute 2000), and case–
control data from a statewide study (the
Collaborative Breast Cancer Study) show
about 20% excess risk for Cape Cod women
older than 50 years of age compared with oth-
ers in Massachusetts, after controlling at the
individual level for many recognized and
hypothesized breast cancer risk factors (Silent
Spring Institute 1998).
In Marin County, where elevated rates of
breast cancer were ﬁrst reported in the 1990s,
incidence increased 6 times faster than
statewide during the 1990s, rising 3.6% per
year (Clarke et al. 2002). A comparison of
Marin County with California census block
groups that were comparable for census charac-
teristics associated with breast cancer risk
showed similar incidence rates in block groups
with similar percentage white population,
urban status, average parity, median household
income, percentage with a college degree,
percentage with a working class occupation,
and percentage below the poverty line (Prehn
and West 1998). Another study reached simi-
lar conclusions but relied on risk factor data for
women 20–55 years of age, an age group
unlikely to be representative of most women
with breast cancer, who tend to be older
(Robbins et al. 1997). Analysis of demographic
factors is not a stopping point for analysis of
rate variations, however, because the SES
variables are not explanatory for disease.
Aside from the role of established breast
cancer risk factors, higher rates of screening
mammography could contribute to higher
reported incidence in a region. For both Cape
Cod and Marin County, available evidence
from patterns of stage at diagnosis (based on
the expectation of more early-stage diagnoses
with mammography) and surveys of mam-
mography use, although not conclusive, is on
the whole not consistent with screening as an
explanation for higher incidence (Clarke et al.
2002; Silent Spring Institute 1998).
An earlier experience in Marin County
illustrates the public health value of drawing
etiologic clues from geographic variation.
Rapidly increasing incidence of endometrial
cancer in Marin County and other affluent
neighborhoods in the San Francisco Bay Area
led to the identification in the 1970s of
estrogen HRT as a causal factor (Austin and
Roe 1979).
Insights from Animal Studies
Epidemiologic studies that consistently show
increased risk associated with multiple sources
of exposure to endogenous and pharmaceuti-
cal estrogen and other hormones strongly
point to the hypothesis that hormonally active
agents in commercial products and pollution
also increase risk. Studies in laboratory ani-
mals, in vitro assays, and wildlife provide fur-
ther evidence of mechanisms for effects of
environmental pollutants on breast cancer risk
through exposure to compounds that mimic
or disrupt hormones that promote or inhibit
tumor growth, act as breast carcinogens, or
affect the development and vulnerability of the
breast. Although the processes by which breast
cancers develop are poorly understood, a
review of the primary features of mammary
gland development and the effects of hor-
mones and chemicals on mammary gland car-
cinogenesis in animal models shows that the
mechanisms that underlie the recognized risk
factors for breast cancer in humans are also
seen in animal studies. This section outlines
current research related to biological mecha-
nisms for breast cancer, including chemical
and hormonal factors and the hypothesis that
hormonally active chemicals—also known as
endocrine disruptors—affect breast cancer.
This information provides the essential scien-
tific foundation for evaluating existing
hypotheses about environmental factors in
breast cancer and generating new hypotheses
and directions for future research.
Mechanistic models for cancer. Historically,
carcinogenesis has been characterized by three
separate stages: initiation, promotion, and
progression. Although the process of carcino-
genesis is now recognized as more complex
than this simple model suggests, the three-
stage model still provides a useful paradigm
by which chemicals can be described based on
a potential mechanism of action (Barrett
1993; Pitot et al. 2000). Initiation is charac-
terized as an irreversible change in a cell, very
probably a genetic change or mutation, result-
ing in a latent neoplastic cell (Appel et al.
1990; Pitot 1993; Pitot and Dragan 1991).
Promotion is the process by which an initi-
ated cell expands clonally into a visible,
benign tumor (Barrett 1993). Experimental
evidence demonstrates that chemically modu-
lated promotion of a cell requires repeated
exposure; endogenous estrogen is thought to
affect the process of mammary carcinogenesis
primarily by this mechanism. Progression is
the term used to describe the irreversible tran-
sition from a benign to malignant tumor,
which involves additional genetic events,
although not necessarily point mutations in
DNA (Barrett 1993; Pitot 1993; Pitot and
Dragan 1991).
Agents that are carcinogens are often
genotoxic, or able to damage DNA. Both ini-
tiation and progression steps involve some
level of genotoxicity, whereas tumor promo-
tion more typically involves stimulation of
cell proliferation. Many agents stimulate cell
proliferation, and there is controversy over
whether these should be considered carcino-
gens unless they can also induce some level of
genetic damage (Alden 2000; Klaunig et al.
2000). Of course, increasing cell proliferation
also increases the opportunity for sponta-
neous mutations, so even promoters can have
some impact on DNA integrity.
Another model for carcinogenesis focuses
on cell–cell interactions that maintain tissue
organization in normal tissue and break down
in carcinogenesis (Sonnenschein and Soto
1999). The role of stromal cells in inhibiting
or promoting carcinogenic progression in
breast epithelia is an ongoing area of research
(Barcellos-Hoff 2001; Barcellos-Hoff and
Ravini 2000; Mueller et al. 2002), and this
work suggests that the study of chemical car-
cinogenesis must consider effects on cell sig-
naling as well as traditional genotoxic effects.
Mammary gland development and
susceptibility. The breast is one of the few
organs that is not fully developed at birth. It
reaches its fully differentiated state only
through the hormonal stimuli induced by
pregnancy and lactation, resulting in portions
of the life cycle with increased susceptibility
to carcinogens. Aspects of development that
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include rates of cell proliferation, stages of cell
differentiation, and prenatal imprinting of
hormonally sensitive tissues.
Greater susceptibility to genotoxic agents
is expected during periods of rapid breast cell
proliferation, such as prenatal, perinatal, and
pubertal time periods and during pregnancy
(Russo and Russo 1996; Wolff et al. 1996).
Rodent studies of dimethylbenzanthracene
(DMBA)-induced mammary tumors have
shown a greater number of tumors and
shorter latency when the carcinogen is admin-
istered to immature animals (Dunnick et al.
1995). Similar findings of increased risk for
earlier age at exposure are observed in human
studies of atomic bomb survivors (Tokunaga
et al. 1987).
In addition to susceptibility during
periods of cell proliferation, the susceptibility
of the mammary gland to carcinogen expo-
sure decreases after the first full-term preg-
nancy, when formerly undifferentiated cells
have developed into fully differentiated cells,
which are less susceptible to genetic damage
and subsequent propagation of the damaged
cell (Neumann et al. 1996; Russo and Russo
1996; Wolff et al. 1996). Epidemiologic stud-
ies have consistently shown that early age of
ﬁrst full-term pregnancy is a protective factor
for breast cancer, and studies in animal mod-
els demonstrate that virgin rats are signifi-
cantly more susceptible to chemically induced
mammary gland cancers than are age-
matched parous rats, which are relatively
resistant to tumors (Brisken 2002; Russo and
Russo 1998). Indeed, ductal and lobular car-
cinomas tend to originate from undifferenti-
ated cells, whereas benign breast tumors tend
to originate from the more differentiated cells
(Russo and Russo 1996). Characterizing the
speciﬁc hormonal factors that are responsible
for the refractoriness of mammary glands
postpregnancy is a topic of ongoing research
(Brisken 2002; Sivaraman and Medina 2002).
Because the breast is particularly
susceptible to carcinogen exposure up until
the ﬁrst full-term pregnancy, there may be an
interaction between risk associated with age at
first pregnancy, an established breast cancer
risk factor, and risk associated with chemical
exposure. In other words, in a hypothetical
group of women with similar lifetime expo-
sures to a mammary carcinogen beginning in
childhood, those who were youngest at their
ﬁrst full-term pregnancy would experience the
lowest increase in risk, and those who were
oldest would experience the greatest increase
in risk.
In addition, a number of studies in
humans and animal models suggest that the
in utero environment affects subsequent breast
cancer risk in offspring (see preceding discus-
sion of human studies). Animal studies have
shown that administration of estradiol or
DES during pregnancy increases breast cancer
rates in female offspring (reviewed in
Hilakivi-Clarke et al. 2001). One mechanism
that has been proposed involves imprinting of
mammary gland tissues in utero, resulting in
an effect on the responsiveness of the tissues
to estrogen later in life.
Hormonal factors in mammary
carcinogenesis. Throughout the life cycle, the
hormonal environment plays a critical role in
the development of breast cancer. Removal of
both ovaries reduces risk, and increased risk
has been observed for women with higher lev-
els of endogenous and pharmaceutical estro-
gen exposure (Henderson and Feigelson
2000). In animal studies, treatment with
chemical carcinogens does not produce mam-
mary tumors in the absence of endogenous
hormones (Russo and Russo 1996, 1998). In
other words, animals that have had their
ovaries removed do not develop mammary
tumors even after exposure to carcinogens.
Supplementing animals with extra estrogens
produces tumors even in the absence of spe-
cific chemical exposures (Russo and Russo
1996, 1998). These findings are consistent
with the idea that estrogens are promoters of
mammary tumors, which act over a long
period of time by causing cell proliferation
and clonal expansion of initiated cells. In
addition, estrogens appear to be required for
mammary carcinogenesis to occur.
Studies of normal mammary gland
development and chemically induced mam-
mary carcinogenesis in animal models have
provided useful information for clarifying
how the interplay of ovarian, pituitary, and
placental hormones, while influencing the
structure, organization, and function of the
mammary gland, modulate its response to
chemical carcinogens. Many hormones and
growth factors have been demonstrated to
affect the tumorigenic response of rats to
genotoxic mammary carcinogens, including
ovarian, placental, pituitary, and thyroid hor-
mones, as well as androgens, insulin, and
many growth factors (Brisken 2002;
Neumann et al. 1996; Russo and Russo 1998;
Sivaraman and Medina 2002; Swanson and
Unterman 2002). In human studies, andro-
gens and insulin-like growth factor 1 have
been shown to be associated with risk of
breast cancer (Toniolo et al. 2000; Wang
et al. 2000).
Some researchers characterize certain
estrogens, including the primary active
endogenous estrogen 17β-estradiol, common
pharmaceutical estrogens, and the synthetic
estrogen DES, as carcinogens on the basis of
their signiﬁcant role in hormonally mediated
cancers in humans and animals (Tsutsui and
Barrett 1997). Others do not consider
endogenous hormones to be carcinogenic
themselves but acknowledge their role as
promoters of carcinogenesis because they
allow neoplastically transformed cells initiated
by other carcinogens to establish and grow by
modifying the target tissue (Russo and Russo
1996, 1998). In addition to acting as pro-
moters, DES, 17β-estradiol, and certain
metabolites of 17β-estradiol, including 16β-
hydroxyestrone, have been shown to exhibit
speciﬁc types of genotoxic activity under cer-
tain conditions (Liehr et al. 1990; Telang
et al. 1992; Tsutsui and Barrett 1997).
Steroidal estrogens are listed as known human
carcinogens in the Report on Carcinogens,
Tenth edition by the U.S. National Toxicology
Program (NTP 2002).
Chemical factors in mammary
carcinogenesis. Experimental studies in ani-
mals offer an alternative means for identifying
potential carcinogens in the environment,
given that epidemiologic studies require a
large number of women, a long duration, and
adequate exposure information. The NTP has
studied the carcinogenic potential of about
500 chemicals in animal carcinogenicity
bioassays. Of these chemicals, 42 caused
mammary tumors in the tests (Bennett and
Davis 2002; Dunnick et al. 1995). These are
listed in Table 1, along with information
about their common uses. These chemicals
include halogenated chemicals and solvents,
including components of gasoline; aromatic
amino/nitro compounds; dyes; and epoxides.
Other research organizations that have con-
ducted animal carcinogenicity bioassays on
specific chemicals have identified about 160
additional chemicals as mammary carcinogens
(Wolff et al. 1996). These include, for exam-
ple, products of combustion [polycyclic aro-
matic hydrocarbons (PAHs), nitro-PAHs],
ionizing radiation, common industrial sol-
vents and other industrial chemicals (vinyl
chloride, vinyl fluoride, vinylidene chloride,
styrene, acrylamide), pesticides (atrazine,
dichlorvos), and other substances (IARC
1999; Pinter et al. 1990). Many of the chemi-
cals identified as mammary carcinogens in
these bioassays also show evidence of geno-
toxicity. For example, in their review of 34
chemicals identiﬁed as mammary carcinogens
by the NTP, Dunnick et al. (1995) report
that 26 showed evidence of mutagenicity in
the Salmonella assay.
Chemicals identiﬁed as mammary carcino-
gens in animal studies are priorities for follow-
up study in humans. Only four of the 42
chemicals tested by the NTP (benzene, 1,3-
butadiene, ethylene oxide, C.I. acid red 114)
have adequate human evidence of carcino-
genicity to be classified as carcinogenic in
humans (NTP 2000). Although the breast is
not the primary tumor site for any of these
four chemicals, many of the human cohorts
studied were all or predominantly male, and
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the breast as a tumor site for ethylene oxide
(the sterilant) and benzene (in gasoline) (see
additional discussion further below) (Hansen
2000; Petralia et al. 1998; Tompa et al. 1999).
In addition, some animal mammary carcino-
gens identiﬁed in other testing programs also
have epidemiologic evidence of breast cancers
from occupational studies, including, for
example, methylene chloride, PAHs, and chlo-
rinated solvents (Hansen 1999, 2000; IARC
1999; Petralia et al. 1999).
Potential role of hormonally active
chemicals. Recent research sheds light on a
class of hormonally active chemicals, referred
to as endocrine disruptors, that may affect
breast cancer primarily by promotional mech-
anisms, as well as by affecting mammary gland
development and responsiveness to other car-
cinogens. The hypothesis has been put for-
ward that exposure to endocrine disruptors,
including chemicals that mimic estrogens,
might play a role in breast cancer risk (Davis
et al. 1993). To date, more than 500 chemi-
cals have been found to be weakly estrogenic
in various assays, including many chemicals in
common use, such as constituents of deter-
gents, pesticides, and plastics (Jobling et al.
1995; Nishihara et al. 2000; Soto et al. 1995).
Table 2 lists selected classes of these chemicals,
speciﬁc examples, and common uses. Many of
these chemicals have been shown to mimic
estrogen in a variety of short term in vitro
assays; they bind the estrogen receptor, initiate
transcription of estrogen-regulated genes, and
can stimulate breast cancer cells in vitro to
proliferate (Korach and McLachlan 1995;
Shelby et al. 1996; Soto et al. 1995). Short-
term in vivo assays, such as increase in uterine
weight in rodents, are also used to demon-
strate estrogenic activity (O’Connor et al.
1996). In addition, effects of these com-
pounds have been frequently observed in
wildlife; for example, widespread sexual dis-
ruption of wild ﬁsh has been reported in rivers
receiving wastewater efﬂuent, which contains a
mixture of endogenous and pharmaceutical
estrogens and industrial chemical endocrine
disruptors (Jobling et al. 1998).
As research in this area continues to
identify estrogenic compounds, significant
questions are raised about how to evaluate
the potential adverse health effects (Rudel
1997). These questions are far from being
resolved. On the one hand, the potency of
many of these endocrine-disrupting pollu-
tants is typically much lower than the
potency of endogenous estrogens, and so it
has been proposed that their effects will be
insigniﬁcant (Safe 1995). On the other hand,
there is particular concern about the effects
of endocrine-disrupting chemicals for expo-
sures that take place when levels of endoge-
nous hormones are very low, such as in utero
or during prepubertal, or postmenopausal
time periods. Also, a number of studies have
demonstrated that multiple estrogenic chemi-
cals can act together to produce an effect
even when each individual component of the
mixture is present below a threshold for
effect, so these pollutants can act in combina-
tion (Silva et al. 2002). Finally, comparison
of the in vivo estrogenic effects of a range of
compounds demonstrates that estrogenic
compounds exhibit diversity in both mecha-
nism and effects (Gould et al. 1998; Rudel
1997). This diversity is attributed, at least in
part, to the fact that the shape of the estrogen
receptor ligand (either estradiol or an
endocrine disruptor) affects the binding of
the receptor–ligand complex to DNA
sequences and subsequent gene expression.
Current research into pharmaceutical selective
estrogen response modifiers (SERMs) for
menopause and breast cancer prevention is an
outgrowth of this phenomenon (Emmen and
Korach 2001). Recent discovery of a second
estrogen receptor, ER-β, complicates matters
further because many hormonally active com-
pounds have differential binding afﬁnities for
the two receptors, and cellular responses to
such stimuli are difficult to predict (Pennie
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Table 1. Chemicals associated with increased incidence of mammary gland tumors in rats and/or mice in
testing by the NTP.a
Chemical Use
Acronycine Pharmaceuticals
Benzeneb Gasoline, solvent
2,2-bis(Bromomethyl)-1,3-propanediol Flame retardant
1,3-Butadienec Auto exhaust, rubber manufacture, gasoline
C.I. acid red 114c Dye for silk, jute, wool, leather
C.I. basic red 9 monohydrochlorided Dye for textiles, leather, paper, biological stain
2-Chloroacetophenone Flame  retardant
Chloroprened Used in neoprene manufacture
Clonitralid Molluskicide
Cytembena Pharmaceuticals
2,4-Diaminotoluened Intermediate in dye synthesis
1,2-Dibromo-3-chloropropaned Soil fumigant, pesticide
1,2-Dibromoethaned Soil fumigate, lead scavenger in gasoline
2,3-Dibromo-1-propanol Flame  retardant
1,1-Dichloroethane Solvent
1,2-Dichloroethane  Solvent, chemical intermediate in insecticide formulations,
gasoline
1,2-Dichloropropane (propylene dichloride)  Chemical intermediate, solvent in dry cleaning ﬂuids, fumigant
Dichlorvos Pesticide
1,2-Dimethoxybenzidine dihydrochlorided Dye intermediate
3,3´-Dimethylbenzidine dihydrochloride Dye intermediate
2,4-Dinitrotoluene  Dye intermediate, explosives, propellants
Ethylene oxideb Sterilizing gas for medical equipment
Furosemide Pharmaceutical
Glycidold Stabilizer in vinyl polymers, intermediate in pesticides and
fragrances
Hydrazobenzened Dye intermediate, tobacco pesticides, motor oil
Isophosphamide Pharmaceuticals
Indium phosphide  Microelectronics, semiconductors, injection lasers, diodes
Isoprene  By-product of ethylene production
Methylene chloride  Solvent, furniture stripper, adhesives
Methyleugenol  Food additive, ﬂavoring, also naturally occurring
Nithiazide Antiprotozoal  compound
5-Nitroacenaphthene Research  chemical
Nitrofurazone Antibiotic
Nitromethane  Rocket and engine fuel, solvent, mining explosive
Ochratoxin Ad Mycotoxin
Phenesterin Pharmaceuticals
Procarbazine hydrochlorided Pharmaceuticals
Reserpined Pharmaceuticals
Sulfallated Herbicide
2,4- and 2,6-Toluene diisocyanated Used in manufacture of ﬂexible polyurethane foams
o-Toluidine hydrochlorided Dye intermediate
1,2,3-Trichloropropaned Chemical intermediate, former solvent and paint remover
Data from Bennett and Davis (2002), Dunnick et al. (1995), IARC (1999), and NTP (2000). 
aListed chemicals caused cancer in mammary glands in one or more of the four typical gender–species experiments con-
ducted on each chemical (i.e., male rats, female rats, male mice, female mice); for example, benzene caused mammary
gland tumors in female mice, whereas glycidol induced tumors of the mammary gland in male and female rats and in
female mice. Overall number of chemicals evaluated in NTP long-term carcinogenesis experiments, 500. Animal mam-
mary carcinogens that were not studied by the NTP are not listed (e.g., PAHs, nitro-PAHs, ionizing radiation, vinyl chlo-
ride, vinyl ﬂuoride, vinylidene chloride, atrazine, styrene, acrylamide; and others). bListed as “known human carcinogen”
in Report on Carcinogens, Ninth edition (NTP 2000); some epidemiologic evidence of breast cancer. cListed as “known
human carcinogen” in Report on Carcinogens, Ninth edition (NTP 2000). dListed as “reasonably anticipated to be human
carcinogen” in Report on Carcinogens, Ninth edition (NTP 2000). et al. 1998). Thus, just because two estrogenic
chemicals cause a similar effect on one out-
come (e.g., uterine weight) does not mean
they will cause a similar effect on all estrogen
receptor–mediated outcomes.
It is of particular interest that certain
dietary constituents that have been hypothe-
sized to be preventive of breast cancer, such
as genistein in soy, are also estrogenic in
many endocrine disruptor screening bioassays
(Adlercreutz et al. 1995). As discussed above,
the relationship between soy food intake and
breast cancer risk in humans is controversial.
In animal studies, genistein treatment often,
but not always, reduced the rate of breast
cancer, with the effect being strongest with
treatment before puberty (Hilakivi-Clarke et
al. 2001). It is hypothesized that the genis-
tein treatment before puberty mimics the
effect of an early pregnancy (this effect has
been demonstrated with estradiol also), thus
reducing the susceptibility of the mammary
gland to carcinogenesis (Hilakivi-Clarke et al.
2001). Additional data from animal and
in vitro studies suggest that phytoestrogens
such as genistein have mixed estrogen
agonist/antagonist activity and can inhibit
the biological response to endogenous estro-
gens, although this apparent antagonist
action may not take place directly via the
estrogen receptor or may be due to the differ-
ential binding of genistein to ER-α and ER-β
(An et al. 2001; Ford 2002; Fotsis et al. 1993;
Lamartiniere et al. 1995; Markaverich et al.
1995; Po et al. 2002). This remains an active
area of research.
Another new and important area of
research related to hormonally active chemi-
cals concerns imprinting of the mammary
gland from in utero exposures to hormones or
hormonally active chemicals. As discussed
above, animal studies and limited human
studies have shown that in utero exposure to
estradiol or DES increases mammary tumor
formation in the offspring (reviewed in
Hilakivi-Clarke et al. 2001). In experiments
related to dietary constituents, maternal
intake of fatty acids and genistein, but not
soy, increased DMBA-induced mammary car-
cinogenesis in the offspring (even though the
soy diet increased pregnancy estrogen levels)
(Hilakivi-Clarke et al. 2001). Limited
research has been conducted on the effects of
in utero exposures to environmental chemicals
on mammary gland development and car-
cinogenesis (reviewed in Birnbaum and
Fenton 2003). However, two studies of in
utero exposure of rats to 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (2,3,7,8-TCDD)
show effects on mammary gland develop-
ment, and one shows increased susceptibility
to chemically induced mammary tumors
(Brown et al. 1998; Fenton et al. 2002). In
addition, increased susceptibility to chemi-
cally induced mammary tumors was observed
in one study of a mixture of organochlorines
[OCs; e.g., dichlorodiphenyltrichloroethane
(DDT), dichlorodiphenyldichloroethylene
(DDE), polychlorinated biphenyls (PCBs)]
given neonatally to rats (Desaulniers et al.
2001), and gestational exposure to atrazine
and bisphenol A have also been shown to
affect mammary gland development in
rodents (reviewed in Birnbaum and Fenton
2003). It is interesting to note that all of the
compounds that have been shown to affect
mammary gland development after gesta-
tional exposure possess some type of direct
endocrine-modulating activity (e.g., estrogen
agonist, androgen antagonist, etc.).
Endocrine disruptors can also act
indirectly, for example, by up- or down-
regulating the enzymes that metabolize
endogenous estrogens or by affecting synthesis
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Table 2. Selected endocrine-disrupting chemicals.
Compound Exposures/uses
Pesticides
Atrazine Selective  herbicide
Chlordane  Insecticide, acaricide, veterinary pharmaceutical
Chlorpyrifos Insecticide,  acaricide
Cypermethrin Insecticide
2,4-Dichlorophenoxyacetic acid Herbicide
DDT (and associated compounds)  Contact insecticide
Dieldrin, aldrin, endrin  Formerly as insecticide
Lindane Insecticide
Malathion Insecticide
Methoxychlor  Insecticide, veterinary pharmaceutical
Pentachlorophenol  Insecticide for termite control, wood preservative
Permethrin, sumithrin  Insecticide
Toxaphene Insecticide
Tributyl tin (chloride)  Biocide, rodent repellent
Vinclozolin Agricultural  fungicide
Persistent nonpesticide OCs and PAHs
PAHs  Compounds present in industrial air pollutants, smoke
from coal or coke-burners, tobacco tar, some foods
Polybrominated biphenyls Formerly as ﬂame retardant
Polybrominated diphenyl ethers  Flame retardants
PCBs (Aroclor 1254) No longer produced commercially—since 1974, in
closed electrical capacitors and transformers; before
1972, in transformers and other electrical equipment, 
carbonless copy paper
Dioxins and furans  Produced during incineration, paper manufacturing, and 
production of chlorine aromatics; impurity in some 
herbicides
Phenols and alkylphenols
Bisphenol A  Polycarbonate and polyester–styrene resins
4-tert-Butylphenol  Intermediate in the manufacturing of varnish and lacquer 
resins, soap antioxidant
Nonylphenol polyethoxylate, 4-nonylphenol, Surfactant, detergent, defoaming agent, some pesticide
4-octylphenol  formulations, degradation product of alkylphenol
ethoxylated antioxidant in some plastics
o-Phenylphenol  Disinfectant fungicide, in the rubber industry
Phthalates
bis(2-Ethylhexyl) phthalate, butyl benzyl phthalate  Commonly used plasticizer for polyvinyl chloride polymers
Di-n-butyl phthalate, diethyl phthalate  Personal care products such as nail polish, perfume, hair
spray, plasticizers, inks, adhesives, other uses
Parabens
Butyl, ethyl, methyl, propyl paraben  Pharmaceutical aid (antifungal), preservative in foods;
in creams, lotions, ointments, other cosmetics
Other organics
Amsonic acid  In manufacturing of dyes, bleaching agents, optical 
brighteners or ﬂuorescent whitening agents
Styrene  Manufacturing plastics, synthetic rubber, resins; insulator
Vinyl acetate  Used in the production of a wide range of polymers, 
including polyvinyl acetate, polyvinyl alcohol; widely used
in production of adhesives, paints, food packaging
Metals
Cadmium, lead  Batteries, plastic stabilizers, pigments
Mercury  Thermometers, dentistry, pharmaceuticals, agricultural
chemicals, antifouling paints, many other uses
Phytoestrogens
Genistein, coumestrol, zearalenone  Soy, grains, grain molds
Data from Budavari (1996), Harris et al. (1997), IARC (1998), Illinois Environmental Protection Agency (1997), Routledge
et al. (1998), Smith and Quinn (1992), Soto et al. (1995), and SRI International (1995).of endogenous hormones (NRC 1999). For
example, effects of alcohol on breast cancer are
hypothesized to be due to a variety of impacts
on cellular signaling pathways, including
increased circulating estrogen and androgen
levels (Ginsburg et al. 1995; Singletary and
Gapstur 2001). Although the focus of research
in this area has been on measuring circulating
serum or urinary levels of endogenous hor-
mones, it is important to note that human
breast tissue can metabolize hormones and
create its own local hormonal environment
independent of circulating levels (Adams
1991; Adams et al. 1992). Thus, effects of
chemicals on the local hormone environment
in the breast may be more relevant than effects
on circulating hormone levels.
Overall, studies in lab animals, in vitro
assays, and wildlife help characterize factors
that influence breast development and car-
cinogenesis. These insights in turn inform
hypothesis generation for human studies and
help interpret findings in these studies.
Toxicological research is a critical avenue for
achieving breast cancer risk reduction because
occupational epidemiology provides little
information on women’s cancers (see next
section). Priorities for toxicologic research are
outlined in the ﬁnal section of this article.
Human Epidemiologic
Evidence
Occupational studies. Despite the strength of
toxicologic evidence for effects of certain pol-
lutants on breast cancer risk, very little human
evidence has accrued. In other areas of cancer
research, leads from the laboratory often are
ﬁrst translated into human research in occu-
pational studies where exposures are higher
and better characterized compared with com-
munity settings, but few occupational studies
have included women, so this resource is
limited for evaluating breast cancer risk.
Elevated incidence has been observed
repeatedly among women in white-collar jobs,
due partly to reproductive risk factors, such as
later childbearing, that are associated with the
higher educational attainment required in
these jobs and with higher SES more broadly.
In some studies, associations are seen for white-
collar jobs after controlling for SES and other
possible confounders. For example, Band et al.
(2000) observed elevated risk for teachers and
medical workers. Calle et al. (1998) reported
elevated risk for executives and secretaries but
not teachers, librarians, or nurses, in a study
that included a crude measure of physical
activity, a potentially important source of con-
founding in studies of occupation and breast
cancer. White-collar jobs do involve chemical
exposures that may be related to breast cancer,
including exposures to indoor pesticides, sol-
vents, second-hand tobacco smoke, and ﬂame
retardants (Spengler et al. 2000), but these
exposures are so poorly understood that most
white-collar job categories are not informative
with respect to questions about environmental
pollutants.
Few studies have investigated breast
cancer risk for women in occupations with
more obvious chemical exposures, even
among nurses, many of whom have substan-
tial chemical exposures and for whom a large
prospective cohort study is already in place
(Nurses’ Health Study 2002). Nurses are
likely to have been exposed to the mammary
carcinogen ethylene oxide (NTP 1998),
which is used to sterilize medical equipment,
and to hormonally active compounds, includ-
ing nonylphenol (used in detergents and plas-
tics) and bisphenol A (used in polycarbonate
plastics) (Aschengrau et al. 1998). Two stud-
ies (Norman et al. 1995; Tompa et al. 1999)
provide weak evidence of an association
between ethylene oxide and breast cancer
among nurses.
A few studies provide evidence of breast
cancer risk associated with exposures to the
mammary carcinogens benzene, PAHs, and
certain organic solvents. Hansen (2000)
reported higher risk of breast cancer for men
exposed to gasoline and vehicular combustion
products, benzene, 1,2-butadiene, 1,2-dibro-
moethane, 1,2-dichloroethane, and PAHs.
With a lag time of at least 10 years, the odds
ratio, adjusted for SES, was 2.5 (95% CI,
1.3–4.5) for exposed men, and the relative
risk was more than 5-fold for men younger
than 40 years of age at diagnosis (odds ratio =
5.4, 95% CI, 2.4–11.9).
Petralia et al. (1999) used interview-based
lifetime job histories and a job-exposure
matrix to assess women’s exposure to benzene
and PAHs, adjusted for breast cancer risk fac-
tors. Exposed jobs involved bus and truck
operators and engine mechanics, molding and
casting machine operators, and garage and
service-station occupations. PAH exposures
independent of benzene are also found in traf-
ﬁc and shipping jobs, and benzene exposures
without PAHs are found among clinical labo-
ratory technologists, painters, and sculptors.
The highest risk was seen for women exposed
to both benzene and PAH, with about 2-fold
increased risk for women ever exposed and
higher risk for women exposed for 4 or more
years. Increased risk of premenopausal breast
cancer was seen among women exposed to
benzene. The risk of PAH exposure could not
be evaluated independent of benzene because
of small numbers. Results provide some evi-
dence of higher risk with longer duration of
exposure and a latency period of 20 or
more years.
Organic solvents, many of which are
animal mammary carcinogens, have also
been associated with breast cancer in an
occupational study of 7,802 Danish women
diagnosed at 20–55 years of age. Breast cancer
risk was increased 20–66%, adjusted for
childbearing and SES, for women employed
longer than a year in jobs with extensive
organic solvent use (Hansen 1999). Exposed
women were employed in nonadministrative
jobs in industries that involved metal prod-
ucts, wood and furniture, printing, chemicals,
and textiles. Risks were more elevated for
women who worked more than 10 years in
these industries and for analyses with 15 or
more years lag time. A 2-fold increased risk
was seen for those with more than 10 years of
employment.
In a case–control study of 995 incident
breast cancers in British Columbia, Band
et al. (2000) reported elevated risk among
women in job titles associated with exposure
to solvents and pesticides. In a study of
Shanghai Cancer Registry data, Petralia et al.
(1998) found breast cancer standardized inci-
dence ratios (SIRs) were most elevated for
women in professional jobs, but SIRs were
also 40% higher for women with high proba-
bility of exposure to organic solvents and ele-
vated for exposure to benzene and medium
and high probability of pesticide exposure,
based on a small number of cases. On the
basis of “usual occupation” in mortality
records for 33,509 cases and 117,794 controls
in 24 states in the United States, Cantor et al.
(1995) reported higher risk associated with
higher probability and level of exposure to
styrene; the widely used organic solvents
methylene chloride, carbon tetrachloride, and
formaldehyde; acid mists; and several metals.
Among 115 earlier studies of occupation
and breast cancer reviewed by Goldberg and
Labreche (1996), a few notable associations
were seen. Two cohort studies reported evi-
dence of higher risk for women in pharma-
ceutical manufacturing, and higher risk was
also reported for women employed as cosme-
tologists or beauticians. Pollan and
Gustavsson (1999) similarly reported elevated
incidence for pharmacists, hairdressers, and
beauticians with SES controlled in a cohort of
women employed in 1970. Both historical
and current risk among hairdressers is of
interest because the mammary carcinogen
vinyl chloride was used in hairspray until the
early 1970s. Knowledge of workplace prac-
tices, more generally, may lead to better
understanding of potentially informative
inconsistencies among occupational studies.
Elevated risk was observed in other
chemical-exposed jobs among metal platers
and coaters (Pollan and Gustavsson 1999),
whereas Goldberg and Labreche (1996)
found little support for higher breast cancer
risk for women in textile production (with
exposure to dyes), dry cleaning (with exposure
to organic solvents), or the nuclear industry.
The negative ﬁnding in the nuclear industry
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increases risk could mean that most workers
were not actually exposed, or it could be due
to protective characteristics of the workforce
in that setting. For example, some jobs may
attract or require women with high levels of
physical activity, or sensitive workers may
develop acute effects such as dermatitis and
central nervous system symptoms that cause
them to leave the workplace. This well-
known phenomenon, referred to as the
“healthy worker effect,” complicates interpre-
tation of negative occupational studies.
Similarly, breast cancer risk among farm
women is of interest because of possible expo-
sure to pesticides, but in general, observed
breast cancer risk is lower among U.S. farm
women, perhaps due to greater levels of physi-
cal activity or patterns in other established
risk factors. Consistent with other studies, the
Carolina Breast Cancer Study found that
women who lived or worked on a farm had
lower risk, but among those who did not wear
protective clothing when applying pesticides,
a 2-fold higher risk of breast cancer was
observed (Duell et al. 2000). Research under
way in the Agricultural Health Study will
provide much better information about farm-
related risk (Alavanja et al. 1994).
Overall, occupational studies provide
fairly consistent evidence that elevated risk
independent of SES is associated with a few
speciﬁc exposures—benzene, organic solvents,
and PAHs—especially for younger workers,
and it is interesting to note that the chemicals
with the most consistent human evidence
have also been identiﬁed as animal mammary
carcinogens (Table 1). Leads from previous
occupational findings and new directions
based on animal studies are priorities for fur-
ther research, although follow-up studies will
be challenging. Some of the challenges are
typical of occupational studies; for example,
workers are typically exposed to mixtures of
chemicals, so speciﬁc exposures and exposure
histories are difﬁcult to reconstruct. In addi-
tion, using surveillance methods that are com-
mon in occupational studies makes it hard to
separate out the effects of chemical exposures
in populations that have protective character-
istics, such as higher physical activity or
lower-risk reproductive patterns. Other chal-
lenges arise from women’s typical work histo-
ries, with exposed women likely to move into
and out of the workforce and to be employed
in dispersed, small-scale settings such as
beauty shops. Goldberg and Labreche (1996)
identify a number of weaknesses common in
the studies they reviewed: reliance on admin-
istrative data and broad job categories as an
indicator of exposure; lack of information on
confounders, including childbearing and SES;
use of mortality as an outcome rather than
incidence, which limits the relevance to
etiology; and low statistical power. Concerted
efforts to overcome these limitations are
important because occupational studies are
the primary means by which chemicals
become identified as human carcinogens
(IARC 1998).
In future studies, possible confounding by
work-related physical activity could be
assessed using job matrix methods that paral-
lel the assessment of chemical exposures.
However, studies that contact workers to
assess a broader range of established breast
cancer risk factors concurrently with work-
place exposures are needed to deal with other
potential confounders. These studies will be
most useful in evaluating chemical exposures
that result in cancers diagnosed during
women’s working years, and longitudinal
follow-up will be required to pick up effects
among older women. Studies of health out-
comes that are known or suspected to be
related to breast cancer risk, including breast
density, fertility outcomes, and age at
menopause, also provide avenues to learn
about breast cancer through occupational
studies without waiting for workers to reach
the older years when breast cancers are typi-
cally diagnosed. The likelihood, based on
effect sizes for established breast cancer risk
factors, that effects of occupational exposures
may be modest in size means that large sam-
ple sizes or meta-analysis of multiple studies
will be needed to discern effects. As more
women move into jobs with substantial
chemical exposure, assessment of occupa-
tional risks will become even more important.
Population-based studies. Population-
based studies have investigated a narrow range
of the compounds identified in the toxico-
logic literature as plausibly relevant to breast
cancer. Certain OC compounds (DDT,
PCBs) have been most studied; because they
are persistent and lipophilic, residues can be
measured in adipose tissue and blood years
after exposure. Most studies to date have
measured residues at the time of diagnosis or
interview and assumed that these recent mea-
sures can be used as proxies for historical
exposures. A few studies have assessed PAHs,
some of which are potent mammary carcino-
gens in animals, and tobacco smoke, mix-
tures with complex toxicologic properties.
Accidental exposures have led to studies of
dioxin (TCDD) and perchloroethylene
(PCE, also called tetrachloroethylene).
The largest recent report is from the Long
Island Breast Cancer Study Project case–
control study that assessed PAHs and certain
OCs, based on blood samples drawn near
the time of diagnosis (cases) or interview
(controls) (Gammon et al. 2002a, 2002b).
PAH exposure was assessed by measuring
PAH–DNA adducts, a measure of DNA
damage from exposure over the previous
months to a few years. Results showed 49%
higher risk, adjusted for breast cancer risk fac-
tors, for the highest compared with the lowest
quintile of adducts (95% CI, 1.00–2.21),
with no evidence of a dose–response relation-
ship (Gammon et al. 2002a). Although the
authors expected grilled food and tobacco
smoke to be the primary sources of PAH, the
lack of relationship between these exposures
and PAH–DNA adducts suggests that other
sources, for example, air pollution, may be
more important. PAH–DNA adducts repre-
sent combined effects of intake and individual
response, so the lack of dose response could
mean that this measure is a better indicator of
individual response than exposure (within the
range of exposures in this study).
The Long Island study showed no
significantly elevated risk associated with
lipid-adjusted blood levels of the OC com-
pounds DDE (the primary metabolite of
DDT), chlordane, dieldrin, or the sum of the
four most common PCB congeners, although
small increases in risk were observed for the
highest compared with the lowest exposure
groups, with no dose–response trend, for
DDE, DDT, and dieldrin (Gammon et al.
2002b). No consistent associations were seen
for subgroups defined by reproductive risk
factors, body size, years of residence on Long
Island, or tumor estrogen- or progesterone-
receptor status.
The results for DDE are consistent with
scientiﬁc evidence that accumulated over the
years during which the Long Island study
took place. Although a few early studies
reported an association with breast cancer,
only 6 of 27 studies reviewed by Snedeker
(2001) reported statistically significant posi-
tive associations. In her review, Snedeker
offers a potential explanation for the many
negative studies. She points out that most
studies rely on DDE as an indicator of previ-
ous exposure to DDT because DDT is not
currently detectable in blood in countries
where DDT was banned years ago. However,
diet (especially meat, fish, and dairy) is a
major ongoing route of exposure to DDE, so
DDE levels in blood represent exposure from
diet as well as DDE metabolized from previ-
ous DDT exposure. DDE is much less hor-
monally active, so it may be that DDT, but
not DDE, contributes to breast cancer, and if
exposure to DDT is poorly measured by cur-
rent blood levels of DDE, studies that rely on
DDE are not informative. In fact, a recent
study by Hoyer et al. (2000a) showed a signif-
icant relationship, with dose response, for
breast cancer risk and p,p´-DDT measured
prospectively in the late 1970s and early
1980s but no association for DDE. In addi-
tion, preliminary results from a California
study using blood drawn during active DDT
use showed increased risk of breast cancer
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measured prospectively in 131 case–control
pairs. The odds ratio was 3.9 (95% CI,
1.4–10.9) for the second versus ﬁrst tertile of
DDT and 10.4 (95% CI, 2.5–43.2) for the
third versus ﬁrst tertile, with a highly statisti-
cally signiﬁcant p-value for trend (Cohn et al.
2002). Additional studies of DDT levels in
women currently exposed around the world
or in blood drawn during years when DDT
was in use in the United States may be
informative.
A series of analyses of the association
between breast cancer and blood levels of
the pesticide dieldrin in Danish women
have shown significant associations and
dose–response trends for 1970s blood levels
and breast cancer incidence (Hoyer et al.
1998) and mortality (Hoyer et al. 2000b).
Mortality was increased more than 5-fold for
women with the highest dieldrin levels aver-
aged across two measurements from the
1970s and early 1980s (relative risk = 5.76;
95% CI, 1.86–17.92) (Hoyer et al. 2000b).
Subgroup analyses showed the strongest asso-
ciations with breast cancer risk for estrogen-
receptor–negative tumors (Hoyer et al. 2001)
and for tumors with p53 mutations (Hoyer
et al. 2002). One potential explanation for
these positive findings compared with other
OC results is that blood measures were taken
closer to the time of dieldrin use, which
ended in the late 1970s, so they are better
indicators of exposure.
Given the many difﬁculties of measuring
historical exposures and characterizing varia-
tion among individuals in community set-
tings, studies of unusual accidental exposures
are a valuable resource. In a study of dioxin in
women who were infants to 40 years of age at
the time of a 1976 industrial accident in
Seveso, Italy, Warner et al. (2002) reported a
2-fold increase in breast cancer risk among
women with a 10-fold increase in serum level
of dioxin (hazard ratio = 2.1; 95% CI,
1.0–4.6). Aschengrau et al. (2002) reported
small to moderate increases in risk for women
on Cape Cod, Massachusetts, exposed to
PCE that leached from vinyl-lined water dis-
tribution pipes (adjusted odds ratios =
1.5–1.9 for > 75th percentile with 0–15 years
of latency). Both of these studies have signiﬁ-
cance beyond the accidental exposure scenar-
ios because dioxin and PCE are common
exposures in everyday settings that could be
reduced through changes in public policy.
Dioxin is a widespread environmental conta-
minant, for example, from waste incineration.
PCE is a solvent commonly used in industry
and in dry cleaning, leading to both worker
and consumer exposures.
Studies of breast cancer and tobacco
smoke, including active smoking or passive
exposure to environmental smoke from
spouses or co-workers or in commercial and
leisure settings, are more numerous than for
other environmental pollutants, in part
because exposure can be easily and inexpen-
sively measured in interviews. Many early
studies found no increased risk among smok-
ers, and a recent meta-analysis of 53 studies
comparing “ever” to “never” smokers found
no association with breast cancer risk
(Collaborative Group on Hormonal Factors
in Breast Cancer et al. 2002). However,
recent studies that separate active from passive
exposure, consider a woman’s age at exposure,
and take into account genetic polymorphisms
that affect the mechanism for ridding the
body of smoke provide some evidence for an
association, although the data are still incon-
sistent (Band et al. 2002; Bartsch et al. 2000;
Dunning et al. 1999; Kropp and Chang-
Claude 2002; Perera 2000).
In general, studies of genetic poly-
morphisms and breast cancer have focused on
genes related to PAH and steroid metabolism
(e.g., CYP, GST, NAT2), and studies of inter-
action between genetic polymorphisms and
environmental pollutants have focused on
tobacco smoke, with two studies of PCBs.
Overall, results of these studies have been
inconsistent (Bartsch et al. 2000; Basham et al.
2001; Dunning et al. 1999), with some evi-
dence of effects of CYP, GST, and NAT2 poly-
morphisms and smoking on breast cancer risk,
particularly in subgroup analyses (Ambrosone
et al. 1996; Bartsch et al. 2000; Chang-Claude
et al. 2002; Firozi et al. 2002; Hunter et al.
1997; Morabia et al. 2000; Zheng W et al.
2002; Zheng T et al. 2002, 2003), and two
positive reports for PCBs and CYP poly-
morphisms in postmenopausal women (Laden
et al. 2002; Moysich et al. 1999).
Overall, the population-based studies of
breast cancer and environment represent a
very sparse literature. Particularly notable is
the focus on smoking and a small number of
persistent OCs. Even for the most-studied
chemicals, the number of studies is relatively
small. In comparison, the recent meta-analy-
ses of pharmaceutical estrogens and breast
cancer are based on nearly twice as many
studies as have been reported for DDT/DDE.
Challenges and Priorities
A variety of challenges in conducting studies
about breast cancer and the environment may
have discouraged work in this area, and these
challenges deﬁne areas where future study will
likely have the greatest impact. In particular,
lack of exposure assessment tools and lack of
toxicologic studies to develop hypotheses
limit the scope of epidemiologic studies. In
addition, issues of timing with respect to
latency and periods of breast vulnerability,
and individual differences in genetic suscepti-
bility are challenges in research design that
require attention. A substantial investment is
needed in basic areas that are the foundation
of successful human research—exposure
assessment, toxicology, and susceptibility—
before we can expect a pay-off from large epi-
demiologic studies of breast cancer and
environment.
Exposure assessment. Multiple aspects of
exposure assessment present methodological
challenges. As in other cancer studies, latency
means that exposures must be assessed for a
time period long before diagnosis. For breast
cancer speciﬁcally, evidence from both animal
and epidemiologic studies suggests that there
may be vulnerable periods, perhaps during
gestation or adolescence or between menarche
and birth of a first child, when exposure is
most important. In addition, effects of envi-
ronmental exposures may differ before and
after menopause, as seen with some previ-
ously studied risk factors (e.g., body mass
index and a recent report on smoking; Band
et al. 2002). These multiple timing considera-
tions are a particular challenge in studying
exposures, such as air and water pollutants,
that women cannot report retrospectively, in
contrast with exposures, for example, child-
bearing history, that comprise the recognized
risk factors. As yet, none of the available bio-
markers can assess exposure dating back many
years, let alone decades, and it is a particular
challenge to characterize exposures for speciﬁc
periods of the life span (e.g., during puberty).
The complexity of mixtures in both occupa-
tional and community settings is another dif-
ficulty, along with simultaneous exposure to
poorly understood degradation products and
metabolites of pollutants.
Recent studies include efforts to improve
exposure assessment in light of these chal-
lenges. Thus, the Long Island study and new
research on tobacco smoke have included a
relatively novel measure of PAH–DNA
adducts. The Cape Cod Breast Cancer and
Environment Study, now under way, deﬁned
development of new exposure assessment
methods as a core goal (Brody et al. 1996).
The study developed a geographic informa-
tion system (GIS), a computer-mapping
database, designed ﬁrst to generate hypothe-
ses and conduct ecologic analyses and later
to assess exposures to wide-area pesticide use
and drinking water contamination at indi-
vidual addresses of 2,100 women in a
case–control study (Brody et al. 2002). GIS
is also being used in exposure reconstruction
in several other epidemiologic studies (Beyea
and Hatch 1999; Lynberg et al. 2001;
Stellman et al. 2003; Ward et al. 2000).
Capitalizing on geographically based
research makes sense in studies of pollutants
because many exposures vary geographically
in relation to sources. Examples of nationally
available data include the Toxics Release
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documents point sources of pollutants, and
records generated under the Safe Drinking
Water Act (1974) for every public drinking
water supply (Caldwell et al. 1998). Although
some exposure data are available nationally,
developing additional GIS exposure data is
often more practical in a geographically
limited area.
Because of enormous gaps in previous
research about breast cancer and environmen-
tal pollutants, beginning with a lack of basic
knowledge about the frequency and level of
exposure to compounds identiﬁed as hormon-
ally active or as animal mammary carcinogens,
exposure studies that investigate these ques-
tions without yet tackling the link to breast
cancer are an efficient way to proceed. For
example, the Cape Cod Study developed an
environmental sampling program for hormon-
ally active compounds and mammary carcino-
gens in groundwater and drinking water,
household air and dust, and women’s urine.
Results documented a potential pathway of
exposure to endocrine disruptors that travel
from septic systems to groundwater and drink-
ing water, and identiﬁed 72 different hormon-
ally active target compounds in homes,
showing substantial opportunity for exposure
(Rudel et al. 1998, 2001, 2002). Compounds
for which frequent or high exposures have
been identified and methods for measuring
exposures developed might then be targeted in
toxicologic and epidemiologic studies.
Considering that the ideal exposure assess-
ment would provide information about the
agent, dose, exposure pathway, timing in rela-
tion to latency, and timing in relation to life-
cycle development, no one measurement
technique is likely to provide a “gold stan-
dard.” Self-report is vulnerable to response
bias and cannot assess pollutant exposures
unknown to the study participant. GIS offers
a new approach to historical exposures and is
independent of knowledge or bias among
study participants, but it is vulnerable to
missing data and faulty models of relation-
ships between indicators and individual expo-
sures. Environmental and biological sampling
methods also may not accurately reconstruct
individual historical exposure. Further, meas-
urement methods have been developed for
only a limited range of compounds, and mea-
surements are expensive and sometimes intru-
sive to collect, resulting in small sample sizes
with low statistical power and possible bias
from nonparticipation. Analyses of relation-
ships among environmental, biological, self-
report, and GIS measures can help inform
interpretation of studies using each of these
exposure assessment methods and help iden-
tify sources of exposure. Studies to character-
ize environmental and biological exposures
can also help identify populations or settings
with high exposures that may provide unique
opportunities for study.
Toxicology and mammary gland biology.
Among 70,000 chemicals in commerce,
fewer than 1,000 have been tested in cancer
bioassays, and there has been no systematic
testing for hormonal activity (U.S. EPA
1999). The challenge of analyzing mixtures
and the idiosyncratic dose–response relation-
ships (e.g., U-shaped) for hormones and hor-
monally active pollutants adds another layer
of complexity. In addition, the biological and
hormonal regulation of mammary gland
development and carcinogenesis is poorly
understood, so forming hypotheses about
how chemicals will affect these processes
is difﬁcult.
Although standard animal bioassays for
identifying carcinogens provide important
direction for study in humans, improvements
are needed in the development and applica-
tion of animal models for mammary tumors
specifically. For example, current protocols
may not adequately address increased suscep-
tibility to carcinogens for early-life exposures
because dosing typically begins in pubertal
animals (Bennett and Davis 2002). In addi-
tion, the rodent strains typically used for car-
cinogenesis bioassays may not be optimal for
identifying mammary carcinogens, either
because of a reduced susceptibility to such
tumors (B6C3F1 mice), because a high back-
ground rate of mammary tumors makes
results difﬁcult to interpret (Fischer 344 rats),
or because hormonal regulation of the rodent
mammary gland differs from that in humans
(Bennett and Davis 2002; Dunnick et al.
1995; Snedeker 2001).
Another important issue for animal mod-
els is that, although it is important to identify
chemical carcinogens that are genotoxic,
which the current protocols are designed to
do, it may also be important to identify chem-
icals that effectively promote the growth of
cells after they have been initiated by some
other carcinogen. The powerful role of
endogenous hormones in promoting breast
tumor development suggests that environmen-
tal chemicals that act as promoters could play
an important role in breast cancer. Assays to
look for tumor-promoting activity involve
treating with a single dose of an initiator and
then following with the promoter. In an assay
like this, DDT was found to accelerate the
rate of mammary tumor formation in male
rats (females were not tested), suggesting that
it could be active as a tumor promoter
(Scribner and Mottet 1981), and wheat bran
was shown to decrease the incidence of
DMBA-initiated mammary tumors (Zile et al.
1998). Finally, it is also a priority to develop
animal models that characterize the effects of
in utero chemical exposures on development
and susceptibility of the mammary gland in
the offspring because in utero hormonal
environments have been shown to affect later
susceptibility to carcinogens (Hilakivi-Clarke
et al. 2001).
Individual susceptibility and intermediate
outcomes. Consideration of individual suscep-
tibility is another area where limitations in
previous research have led to recent innova-
tion. Although high-risk breast cancer genes
account for a small fraction of cases, lower
risk, more common genetic polymorphisms
that affect metabolism of endogenous estro-
gen and other chemicals are promising direc-
tions for study, as discussed above. However,
studies to date have yielded conﬂicting results,
in part because of the need for large sample
sizes to achieve adequate statistical power and
because of limited information on specific
functional outcomes of the polymorphisms in
relation to mechanisms of breast carcinogene-
sis (Dunning et al. 1999; Friedberg 2001;
Perera 2000; Pharoah et al. 2002). This is
another aspect of basic biology that could
advance our ability to study breast cancer.
The difﬁculties of linking exposures with
disease may also be remedied by studies of
intermediate outcomes and of interactions or
effect modiﬁcation associated with recognized
breast cancer risk factors. Studies of effects of
chemical exposures on puberty, breast den-
sity, and in situ disease—all recognized risk
factors for breast cancer—reduce the time lag
between exposure and outcome measurement.
Research to identify new intermediate out-
comes, such as hallmarks of mammary gland
development, will add to tools available for
addressing breast cancer etiology.
Conclusion
Although journalistic reports have recently
implied that scientific evidence shows that
environmental pollutants are unrelated to
breast cancer (Associated Press 2002; Kolata
2002), a review of research in this area reveals
a much different picture of major knowledge
gaps, difficult challenges in research design,
and contrasting bodies of evidence from toxi-
cologic and epidemiologic studies. Strong
toxicologic evidence points to a large number
of ubiquitous pollutants that are plausibly
linked to breast cancer because they mimic or
disrupt hormones known to affect breast can-
cer risk, initiate mammary tumors in animals,
or permanently alter breast development,
affecting susceptibility. Epidemiologic
research is far more limited because very few
of the compounds identiﬁed as endocrine dis-
ruptors or animal mammary carcinogens have
ever been targeted in a human breast cancer
study. A small but interesting body of occu-
pational studies that link higher risk with jobs
involving likely exposures to organic solvents
and PAHs is generally consistent with animal
studies. The relatively few population-based
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negative overall, with positive results often
limited to subgroups. Many plausible reasons
for null epidemiologic results have been
advanced in this article and elsewhere, includ-
ing poor historical exposure measurement,
restriction to a small number of pollutants,
failure to study compounds in current use,
low statistical power to detect modest effects,
and failure to take into account genetic sus-
ceptibility or life-cycle effects. Limited study
of women in occupational settings where
exposures are relatively high and well deﬁned
is another barrier to understanding chemical
risks. Given the modest relative risks associ-
ated with the recognized breast cancer risk
factors, an integrated research agenda for
study of environmental pollutants in both
laboratory and human settings has great
potential. Even if the relative risks of environ-
mental factors are modest, discovery of a risk
that can be modified would save many
thousands of lives.
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